Maze Therapeutics, Inc. Common Stock (MAZE) - Total Assets
Based on the latest financial reports, Maze Therapeutics, Inc. Common Stock (MAZE) holds total assets worth $419.71 Million USD as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Check Maze Therapeutics, Inc. Common Stock (MAZE) reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
Maze Therapeutics, Inc. Common Stock - Total Assets Trend (2022–2025)
This chart illustrates how Maze Therapeutics, Inc. Common Stock's total assets have evolved over time, based on quarterly financial data. Explore Maze Therapeutics, Inc. Common Stock strategic investment ratio to see how much of total assets are deployed in long-term investments.
Maze Therapeutics, Inc. Common Stock - Asset Composition Analysis
Current Asset Composition (December 2025)
Maze Therapeutics, Inc. Common Stock's total assets of $419.71 Million consist of 88.1% current assets and 11.9% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 47.7% |
| Accounts Receivable | $1.50 Million | 0.4% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2022–2025)
This chart illustrates how Maze Therapeutics, Inc. Common Stock's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see MAZE market cap.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Maze Therapeutics, Inc. Common Stock's current assets represent 88.1% of total assets in 2025, an increase from 70.8% in 2022.
- Cash Position: Cash and equivalents constituted 47.7% of total assets in 2025, down from 66.6% in 2022.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2022.
- Asset Diversification: The largest asset category is accounts receivable at 0.4% of total assets.
Maze Therapeutics, Inc. Common Stock Competitors by Total Assets
Key competitors of Maze Therapeutics, Inc. Common Stock based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Ascendis Pharma AS
NASDAQ:ASND
|
USA | $2.01 Billion |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $8.59 Billion |
|
Spyre Therapeutics Inc.
NASDAQ:SYRE
|
USA | $763.95 Million |
|
3SBio Inc
F:83B
|
Germany | €36.25 Billion |
|
Soleno Therapeutics Inc
NASDAQ:SLNO
|
USA | $608.39 Million |
|
Jiangxi Fushine Pharmaceutical Co Ltd
SHE:300497
|
China | CN¥4.48 Billion |
|
Novavax Inc
NASDAQ:NVAX
|
USA | $1.04 Billion |
|
BB Biotech AG
SW:BION
|
Switzerland | CHF2.64 Billion |
Maze Therapeutics, Inc. Common Stock - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 17.88 | 16.10 | 2.09 |
| Quick Ratio | 17.88 | 16.10 | 2.09 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $358.54 Million | $281.09 Million | $17.79 Million |
Maze Therapeutics, Inc. Common Stock - Advanced Valuation Insights
This section examines the relationship between Maze Therapeutics, Inc. Common Stock's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 4.11 |
| Latest Market Cap to Assets Ratio | 3.38 |
| Asset Growth Rate (YoY) | 65.1% |
| Total Assets | $397.13 Million |
| Market Capitalization | $1.34 Billion USD |
Valuation Analysis
Premium Asset Valuation: The market values Maze Therapeutics, Inc. Common Stock's assets at a significant premium (3.38x), suggesting investors see substantial growth potential or unique competitive advantages.
Rapid Asset Growth: Maze Therapeutics, Inc. Common Stock's assets grew by 65.1% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Maze Therapeutics, Inc. Common Stock (2022–2025)
The table below shows the annual total assets of Maze Therapeutics, Inc. Common Stock from 2022 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $397.13 Million | +65.10% |
| 2024-12-31 | $240.54 Million | +236.40% |
| 2023-12-31 | $71.50 Million | -52.32% |
| 2022-12-31 | $149.96 Million | -- |
About Maze Therapeutics, Inc. Common Stock
Maze Therapeutics, Inc., a clinical stage biopharmaceutical company, develops small molecule precision medicines for the treatment of kidney and metabolic diseases in the United States. Its lead programs include MZE829, an oral small molecule inhibitor of apolipoprotein L1, or APOL1, which is in phase II clinical trial for the treatment of patients with APOL1 kidney disease; and MZE782, an oral s… Read more